Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 785 for healing of fresh tibial shaft fractures after intramedullary nailing
NL-OMON32518Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tibial diaphyseal fracture comparing AMG 785 with Placebo (2 arms). Primary endpoint: Time to radiographic healing. Planned start Nov 2009; status: withdrawn.
02
Drugs
romosozumab
03
Conditions
tibial diaphyseal fracture
Beyond the preview
Go deeper on NL-OMON32518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32518.